ocal application of drug 5- FLUOROURACIL as a Medication THERAPY following removal of tumour called AMELOBLASTOMA
Phase 4
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2024/03/064106
- Lead Sponsor
- Dr Priyanka Shetty
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) All the Histopathologically diagnosed cases of Ameloblastoma reporting in OPD.
2) All patients willing and fit for surgery.
3) All the cases who are undergoing treatment for the 1st time.
Exclusion Criteria
1) Patients with diagnosis other than Ameloblastoma reporting in OPD
2) Patients unwilling and unfit for surgery.
3) Patients who are lost to follow up.
4) Recurrent cases or Aggressive Case of Ameloblastoma.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Nerve Paresthesia <br/ ><br>2) Radiographic Healing of lesion <br/ ><br>3) Recurrence of lesionTimepoint: 1) Nerve Paresthesia - pre-op, post-op, 1 month, 3 months, 6 months, 1 year, 1 year 6 months, 2 years. <br/ ><br>2) Radiographic Healing of lesion - pre-op, post-op, 1 month, 3 months, 6 months, 1 year, 1 year 6 months, 2 years. <br/ ><br>3) Recurrence of lesion - pre-op, post-op, 1 month, 3 months, 6 months, 1 year, 1 year 6 months, 2 years
- Secondary Outcome Measures
Name Time Method Volumetric Analysis of the cavity following excision.Timepoint: Pre-op - S0 <br/ ><br>6 months post -op - S1 <br/ ><br>12 months post-op - S2